entertainment -WSS

entertainment

author：Wikipedia 2025-09-30 16:28:18 - browse：81924

The New York Stock Exchange (NYSE) — Spencer Platt/Getty Images

Biohaven Pharmaceuticals said Wednesday that a new type of experimental medicine reduced levels of a disease-causing immune molecule by up to 37% in an early-stage study of human volunteers — a result that the company called “positive” as a proof of concept but that also fell short of investor expectations.

The drug, called BHV-1300, belongs to a new class of antibody medicines that shuttle harmful proteins to the liver so they can be removed from the body. BHV-1300 is specifically designed to reduce levels of an autoantibody called IgG that is implicated in rheumatoid arthritis, myasthenia gravis, and other autoimmune disorders.

In its Phase 1 study, Biohaven tested four escalating doses of BHV-1300 in healthy volunteers, showing a reduction in levels of IgG of 5%, 15%, 30%, and 37%, respectively, the company said. The reductions in IgG levels, which occurred relatively quickly in just four to five days, did not cause significant, adverse changes in liver enzyme levels, Biohaven added — an important safety check given the mechanism of the drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Scientists grapple with ethics of stem cell research

WSS

How AI helped researchers track recovery from depression

Biotech lab space demand falls sharply

How Vertex's cystic fibrosis drug is changing patients' lives

It's been 20 years since Dolly the sheep. Where's my clone?

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Readout LOUD podcast: possible new ALS drug, artificial wombs

focus

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Malaria cases in Florida and Texas: Here’s what you need to know

Thousands of UK hospital doctors walk out in the latest pay dispute, crippling health services

Medical records are filled with copy

US jobless claims fall again as labor market continues to flash strength

BioMarin wins approval for gene therapy to treat hemophilia A

Readout LOUD podcast: possible new ALS drug, artificial wombs

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Emergency workers more likely to restrain Black patients: study

George Santos makes 1st court appearance after pleading not guilty to 13 counts

There’s a way to spot data fakery. All journals should be using it

hotspot

Senate HELP committee spars over health care workforce policies

Second xenotransplant done with gene

Senators: Long

EpiPen alternative approval delay highlights citizen petition issue

How AI helped researchers track recovery from depression

FDA panel to weigh approval of NurOwn, controversial ALS drug

entertainment

leisure time

leisure time

focus